Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Status:
Terminated
Trial end date:
2012-09-13
Target enrollment:
Participant gender:
Summary
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205
and either progressed while on study or discontinued due to unacceptable toxicity related to
etoposide were allowed to participate in this study to assess the safety profile of
single-agent erlotinib in participants with recurrent or refractory pediatric ependymoma.